| Document |
Document Title |
|
WO/2024/053091A1 |
[Problem] The purpose of the present invention is to develop a low-cost and higher aspect ratio material that is available as a substitute for conventional high aspect ratio magnesium hydroxide which requires a large amount of a monocarb...
|
|
WO/2024/037067A1 |
A cationic oligomeric surfactant containing multiple quaternary ammonium head groups and a preparation method therefor. The preparation method comprises: dropwise adding a quaternization reagent into an acidified C1-C18 alkyl tertiary am...
|
|
WO/2024/033705A1 |
Disclosed herein are methods and compositions for involving a xanthine oxidase inhibitor that has enhanced solubility. The compositions described herein include a xanthine oxidase inhibitor combined with an organic base. The compositions...
|
|
WO/2024/028423A1 |
The present invention relates to an efficient and industrially applicable process for the preparation of 2-substituted morpholine derivatives such as viloxazine and to intermediates useful therefor.
|
|
WO/2024/016638A1 |
An antihistamine compound having a structure represented by formula (I), a pharmaceutically acceptable salt and a preparation method therefor, and a use of the antihistamine compound having a structure represented by formula (I) and the ...
|
|
WO/2024/011239A1 |
Provided herein are substituted quaternary amine salt compounds and compositions thereof for inhibiting production of trimethylamine (TMA), as well as inhibiting the conversion of choline to trimethylamine, and such compounds, and compos...
|
|
WO/2023/242424A1 |
The present invention relates to new carbohydrate derivatives ((O) and (l-oxide). The derivatives can be prepared via a method that involves direct amination. The derivatives can be used for various applications, for instance as surfacta...
|
|
WO/2023/230649A1 |
The present disclosure relates to compounds of formula (I), their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.
|
|
WO/2023/229295A1 |
The present invention relates to a phenylpropene derivative, and a pharmaceutical composition for the prevention or treatment of cancer, comprising the phenylpropene derivative as an active ingredient. The phenylpropene derivative disclo...
|
|
WO/2023/229293A1 |
The present invention relates a bicycle derivative and a pharmaceutical composition comprising same as an active ingredient for the prevention or treatment of cancer. Found to have ACC inhibitory activity involved in the inhibitory mecha...
|
|
WO/2023/224418A1 |
The present invention relates to a method for producing, from fatty alcohols, various monomers that are used in the production of synthetic resins.
|
|
WO/2023/214360A1 |
A method to increase the stability of an aqueous composition comprising an alkanolamine, said method comprising the steps of: - providing a vessel; - adding a pre-determined amount of water into said vessel; - adding a pre-determined amo...
|
|
WO/2023/206874A1 |
A sacubitril intermediate, a preparation method therefor, and use thereof. A key intermediate N-Boc amino alcohol represented by formula (10) or formula (10-a) can be efficiently prepared. The intermediate can be used to prepare a neutra...
|
|
WO/2023/209033A1 |
In one aspect, the present invention relates to a method for crystallizing (2R,3R)-3-(3- methoxyphenyl)-N,N,2-trimethylpentan-1-amine or salts thereof (compound I), the method comprising the following steps: (i) mixing compound I with a ...
|
|
WO/2023/196527A2 |
Novel ionizable lipids, compositions, and methods of using the novel ionizable lipids and compositions are disclosed. Lipid nanoparticle compositions include a novel ionizable lipid as well as additional lipids such as phospholipids, str...
|
|
WO/2023/187051A1 |
A process for the production of a surfactant is provided, as well as a surfactant composition. Moreover, specific surfactants and compositions thereof are provided, as well as their use in a wide variety of applications such as all purpo...
|
|
WO/2023/190130A1 |
Provided is an aqueous fibroin solution having high storage stability and excellent foam formation ability, and a production method thereof. This aqueous fibroin solution contains fibroin and a compound represented by general formula (1)...
|
|
WO/2023/191088A1 |
The present invention provides a polysaccharide which has a degree of polymerisation of 16-40 and is composed only of galactose or composed only of galactose and 1-3 molecules of arabinose, the saccharide units of said polysaccharide bei...
|
|
WO/2023/182171A1 |
This carbon dioxide separation material contains a polyamine. The polyamine contains an isopropyl polyamine component which has a hydrogen atom or a functional group bonded to a nitrogen atom and has two or more isopropyl groups bonded t...
|
|
WO/2023/182173A1 |
This carbon dioxide isolator includes polyamine. The polyamine includes a propyl polyamine component having a hydrogen atom or a functional group that bonds to a nitrogen atom and having three or more propyl groups which bond to respecti...
|
|
WO/2023/175526A1 |
The present invention generally relates to a process for preparation of azabicyclo [3.1.0] hexane intermediate of Formula (I), an intermediate for preparation of certain antiviral compounds for example boceprevir and nirmatrelvir. Wherei...
|
|
WO/2023/166983A1 |
The present invention provides a phosphite ester composition represented by formula (1), comprising a phosphite ester compound and an amine compound (A) having a hydroxyalkyl group, wherein the content of the amine compound (A) is 0.01-1...
|
|
WO/2023/158607A1 |
Disclosed herein are thyroid receptor agonist compounds, polymorphic forms, pharmaceutical compositions, the method of use, and preparation thereof. Some embodiments relate to crystalline forms of Compound 1 and salts thereof.
|
|
WO/2023/143601A1 |
Provided in the present invention are a novel cationic lipid, a lipid nanoparticle and a nucleic acid vaccine. In the present invention, a specific cationic lipid is selected for preparing a lipid nanoparticle mRNA vaccine, which is foun...
|
|
WO/2023/143600A1 |
The present invention provides a novel cationic lipid, a lipid nanoparticle, and a nucleic acid vaccine. According to the present invention, a specific cationic lipid is selected to prepare a lipid nanoparticle mRNA vaccine, and the lipi...
|
|
WO/2023/143591A1 |
The present invention provides a novel cationic lipid, a lipid nanoparticle and a nucleic acid vaccine. It is found that the lipid nanoparticle mRNA vaccine prepared in the present invention by selecting a specific cationic lipid has bet...
|
|
WO/2023/135035A1 |
A process for the manufacture of alkanolamines and/or a process for the conversion of al-kanolamines wherein the process is performed in one or equipment items, wherein one or more steel parts of the one or more equipment items, which ha...
|
|
WO/2023/109213A1 |
A method for preparing a chiral amine compound B or C, which can be used for synthesizing an optically pure repotrectinib intermediate, wherein 2-hydroxy-5-fluorophenylalkylketone compound A is used as a raw material, and a corresponding...
|
|
WO/2023/108172A2 |
Disclosed herein are compounds of the formula wherein R1 is methyl; R2 is selected from hydrogen, deuterium, and methyl, or R1 and R2 together with the atom to which they are attached form a cyclopropyl; R3 and R4 independently are selec...
|
|
WO/2023/098592A1 |
The present invention provides a carbon-loaded iron-based catalyst, and a preparation method thereof and a use. The preparation method comprises dissolving ferric chloride in water, adding activated carbon, adding sodium hydroxide at 60-...
|
|
WO/2023/098882A1 |
Provided herein are diastereomer-selective synthetic methods and intermediates for making chiral 3, 5-disubstituted morpholine compounds, which are useful for the preparation of compounds useful as mitochondrial-derived activator of casp...
|
|
WO/2023/085042A1 |
Provided is a method for recovering carbon dioxide, that includes: a first step in which an aqueous amine solution that contains a amine compound is caused to absorb carbon dioxide in a gas containing carbon dioxide; and a second step in...
|
|
WO/2023/077824A1 |
The present invention relates to the technical field of drug synthesis, and relates to a preparation method for dopamine hydrochloride. Specifically, the preparation method for dopamine hydrochloride of the present invention comprises th...
|
|
WO/2023/072434A1 |
The invention relates to new spermine derivatives of Formula (I), wherein the meaning of the groups R1, R2, n and m is defined in the description, to a pharmaceutical composition thereof and to their use as heparin antidotes in the contr...
|
|
WO/2023/076997A1 |
The invention relates to polydeuterated analog forms of ambroxol and related compounds (including bromhexine and the ambroxol salt, ambroxol hydrochloride), compositions comprising same, and methods of preventing and/or treating various ...
|
|
WO/2023/067561A1 |
The use of an ionizable cationic lipid in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, including conventional messenger RNA and self-amplifying messenger RNA, an...
|
|
WO/2023/056418A1 |
The present disclosure relates, in part, to lipid nanoparticles (LNPs) comprising cholesterol substitutes (i.e., cholesterol analogs and/or derivatives) and methods of use thereof for in vivo delivery of nucleic acid molecules and/or the...
|
|
WO/2023/050583A1 |
A method for preparing tris(hydroxymethyl)aminomethane of the present invention, comprising: a process of preparing tris(hydroxymethyl)aminomethane by continuous catalytic hydrogenation of tris(hydroxymethyl)nitromethane is carried out i...
|
|
WO/2023/056282A1 |
The present disclosure relates, in part, to immune cell targeted lipid nanoparticle (LNP) compositions, and methods of use thereof for in vivo delivery of nucleic acid molecules and/or therapeutic agents to a target cell. In certain embo...
|
|
WO/2023/046768A1 |
The invention relates a method for producing amine N-oxide compounds of the formula (I) or (II), in which the R1 are selected from hydrocarbon groups with 4 to 26 C atoms and optionally at least one O or S atom; R2, R3, and R5 are select...
|
|
WO/2023/048034A1 |
The present invention addresses the problem of providing a method for producing an aromatic compound having an ethynyl group by means of a simple and inexpensive coupling reaction using a halogen-containing aromatic compound. The prese...
|
|
WO/2023/047283A1 |
A new composition of matter has the molecular structure [I] : Formula (I) wherein R1 is an alkyl, cycloalkyl, aralkyl group having ≥ 1 to ≤ 10 carbon atoms; R2 is selected from the group consisting of an aliphatic C1-C10 group, an un...
|
|
WO/2023/046882A1 |
There is provided herein compounds of formula I and pharmaceutically acceptable salts thereof, wherein X1, X2, Z, the ring containing Q1 to Q5, m and r have meanings as provided in the description. There is also provided medical uses of ...
|
|
WO/2023/027105A1 |
Provided is a composite amine absorbing liquid or the like that has a high reaction rate. This composite amine absorbing liquid is for absorbing CO2 and/or H2S in a gas, and contains (a) a chain-like monoamine, (b) a diamine including am...
|
|
WO/2023/028524A1 |
Antidegradant products are disclosed that may be made by a process comprising: hydroformylating one or more of: a fatty acid or fatty acid derivative having one or more unsaturations, e.g., carbon-to-carbon double bonds, and from 10 to 2...
|
|
WO/2023/017527A1 |
The present invention relates to an additive comprising stearic acid and ethanolamine. The invention also relates to a process for the preparation of said additive. The present additive significantly improves the silica filler dispersion...
|
|
WO/2023/017323A1 |
In this invention, the active substance of choline chloride is produced using copper and molybdenum based heterogeneous nanocatalysts which is a food supplement for livestock, poultry and aquatic animals and increases productivity. Choli...
|
|
WO/2023/010213A1 |
The present invention provides anti-fungal compositions comprising at least one unsaturated fatty acid or a pharmaceutically acceptable salt thereof; at least one alpha-hydroxy acid or a pharmaceutically acceptable salt thereof; and at l...
|
|
WO/2023/013697A1 |
Provided are a material for metal patterning that can suppress, to a high degree, the formation of a metal thin film on a film surface, a fluoro compound, a thin film for metal patterning that uses the material and the fluoro compound, a...
|
|
WO/2023/279836A1 |
Provided are an ionizable lipid compound of formula I for nucleic acid delivery and an LNP composition thereof, which can efficiently and stably deliver a biologically active substance to a target cell or an organ. The mRNA LNP prepared ...
|
